Avidity Biosciences

63 articles with Avidity Biosciences

• Avidity Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

  5/10/2022

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced financial results for the first quarter ended March 31, 2022 and highlighted recent corporate progress.       

• Avidity Biosciences Expands Role of Michael MacLean to Chief Financial and Chief Business Officer

  4/5/2022

  Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that Michael MacLean, currently the chief financial officer, has expanded his role to include responsibilities as chief business officer.

• Avidity Biosciences Announces Upcoming Presentations at the American Academy of Neurology 2022 Annual Meeting

  3/29/2022

  Avidity Biosciences, Inc.  today announced they will be presenting at the American Academy of Neurology 2022 Annual Meeting in Seattle, Washington , April 2-7, 2022.

• Avidity Biosciences Announces Upcoming Presentations at the 2022 MDA Clinical & Scientific Conference

  3/7/2022

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced they will be presenting an oral presentation and multiple poster presentations at the 2022 MDA Clinical & Scientific Conference.

• Avidity Biosciences Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Highlights

  3/1/2022

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended December 31, 2021 and highlighted recent corporate progress. 

• Avidity Biosciences Appoints Steve Hughes, M.D., as Chief Medical Officer

  2/23/2022

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of Steve Hughes, M.D. as chief medical officer.

• 

  Five Top CEOs to Watch in 2022

  2/23/2022

  Several CEOs have stood out from their peers throughout the past year, winning recognition from the Healthcare Technology Report. BioSpace looks at five of these leaders.

• Avidity Biosciences to Participate in Upcoming Investor Conferences - Feb 11, 2022

  2/11/2022

  Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the Avidity management team will be participating at the following conferences.

• Avidity Biosciences Highlights FSHD Program at Virtual Investor and Analyst Event

  12/9/2021

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it will be hosting a live webcast investor and analyst day event titled "Volume 3: Delivering on AOCs - FSHD" at 11:00am ET.

• Avidity Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights

  11/9/2021

  Avidity Biosciences, Inc. (Nasdaq: RNA), today reported financial results for the third quarter and nine months ended September 30, 2021 and highlighted recent corporate progress.

• 

  Clinical Catch-Up: November 1-5

  11/8/2021

  The first week of November was marked by numerous clinical trial announcements. Here’s a look.

• Avidity Announces First Person Dosed with an Antibody Oligonucleotide Conjugate (AOC™)

  11/4/2021

  Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the first participants in the Phase 1/2 MARINA trial have been dosed with Avidity's lead AOC product candidate, AOC 1001, marking the first time a person has been dosed with an AOC.

• Avidity Biosciences to Participate in Upcoming Investor Conferences - Nov 02, 2021

  11/2/2021

  Avidity Biosciences, Inc. a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the Avidity management team will be participating at the following conferences.

• FDA Grants Fast Track Designation to AOC 1001 for the Treatment of Myotonic Dystrophy Type 1

  10/18/2021

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its lead program, AOC 1001, for the treatment of myotonic dystrophy type 1 (DM1).

• Avidity Biosciences to Participate in Upcoming Investor Conferences - Aug 31, 2021

  8/31/2021

  Avidity Biosciences, Inc. a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the Avidity management team will be participating at the following conferences

• European Medicines Agency (EMA) Grants Orphan Designation for AOC 1001

  8/24/2021

  Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the European Commission has granted orphan designation for AOC 1001.

• Avidity Biosciences Enters Into Collaboration with FSHD Clinical Trial Network to Support Development of Biomarkers for Future Clinical Trial Use

  8/16/2021

  Avidity Biosciences, Inc. today announced its collaboration with the Facioscapulohumeral Muscular Dystrophy (FSHD) Clinical Trial Research Network (FSHD CTRN) to support a natural history study for people living with FSHD called the Motor Outcomes to Validate Evaluations Plus (MOVE+) Study.

• Avidity Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

  8/9/2021

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the second quarter and six months ended June 30, 2021 and highlighted recent corporate progress.

• Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock

  8/3/2021

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $18.00 per share.

• Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock - Aug 02, 2021

  8/2/2021

  Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that it intends to offer and sell, subject to market and other conditions, $100 million of shares of its common stock in an underwritten public offering.